| Outcome | All | CRKL | p-value† | CK2 β | p-value† | |||
| Low | High |
| Low | High |
| |||
| Progression Free Survival | (N = 28) | (N = 6) | (N = 22) |
| (N = 5) | (N = 23) |
| |
| Mean (months) (95% CI) | 32.11 months (23.96 - 40.26) | 37.67 months (25.29 - 50.04) | 17.54 months (12.42 - 22.66) | 0.008 | 41.20 months (30.08 - 52.31) | 17.65 months (12.77 - 22.53) | 0.013 | |
| 1 year PFS | 64.3% | 100% | 54.5% |
| 100% | 56.5% |
| |
| 2 year PFS | 64.3% | 100% | 54.5% |
| 100% | 56.5% |
| |
| 3 year PFS | 64.3% | 100% | 21.8% |
| 100% | 22.6% |
| |
| 4 year PFS | 45% | - | 21.8% |
| - | 22.6% |
| |
| 5 year PFS | - | - | - |
| - | - |
| |
| Overall Survival | (N = 50) | (N = 22) | (N = 28) |
| (N = 21) | (N = 29) |
| |
| Mean (months) (95% CI) | 46.13 months (40.82 - 51.45) | 57.61 months (54.48 - 60.75) | 34.18 months (27.40 - 40.96) | <0.001 | 57.61 months (54.48 - 60.75) | 34.63 months (27.94 - 41.32) | <0.001 | |
| 1 year OS | 88% | 100% | 78.6% |
| 100% | 79.3% |
| |
| 2 year OS | 79.3% | 100% | 61.2% |
| 100% | 62.8% |
| |
| 3 year OS | 66.9% | 90.5% | 44.5% |
| 90.5% | 45.6% |
| |
| 4 year OS | 64.4% | 90.5% | 39% |
| 90.5% | 39.9% |
| |
| 5 year OS | 56.8% | 90.5% | - |
| 90.5% | - |
| |